Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do
not have activating mutations in the tyrosine kinase domain of the epidermal growth factor …

Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and
the leading cause of human cancer deaths worldwide [1]. While it has been the most …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

Lung cancer is the leading cause of cancer related mortality worldwide. Non-small cell lung
cancer (NSCLC) accounts for 85% of all cases. Half of the patients at diagnosis of NSCLC …

Platinum-based chemotherapy is the standard treatment for patients with advanced non-
small cell lung cancer (NSCLC), but the evidence of its efficacy among ECOG performance …

A MESSAGE FROM ASCO'S PRESIDENT I am delighted to present you with “Clinical
Cancer Advances 2012: Annual Report on Progress Against Cancer From the American …

Lung cancer remains the number one cause of cancer-related death in the United States
among both men and women. It is estimated that in 2013, there will be more than 200,000 …

Purpose Platinum-based doublet chemotherapy is the treatment of choice for patients with
non-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet as …

Introduction: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death
worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have …